Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 31, 2006 Michael P. Cecil	An Opening for Plavix New data suggesting problems with drug-eluting stents may translate into more sales of the blood thinner Plavix and fewer sales of the stents. Investors, take note.
BusinessWeek April 17, 2006 Amy Barrett	Unclogging J&J's Pipeline Maker of coronary stents Johnson & Johnson needs to release more products and grab back its lead in the crowded market it created.
The Motley Fool June 1, 2005 Stephen D. Simpson	Stent Wars: Revenge of the Bypass A new study supports a long-held belief that bypass surgery is better than using stents. What does it mean for stent makers and investors?
The Motley Fool October 25, 2007 Brian Orelli	Time to Invest in Stents? Stent devices have seen slumping sales over the last few years. Is it time now to invest in the companies that produce them?
The Motley Fool December 13, 2006 Matthew Crews	Less Support for Drug-Eluting Stents? The FDA responds to a recent controversy. The regulator's stance represents a good-faith-take on the newer stents, which is good news for drug companies.
The Motley Fool February 5, 2008 Brian Orelli	Medtronic Endeavors to Compete The U.S. drug-eluting stent market just got a little more crowded, after Medtronic announces that the FDA had approved its Endeavor stent for marketing in the U.S.
BusinessWeek October 9, 2006 John Carey	"No One Wanted To Hear" Renu Virmani warned that, over time, some drug-coated stents could lead to fatal clots.
Managed Care June 2006 Tom Pope	Hard to Curb Overuse of Drug-Eluting Stents Health plans find themselves paying for the latest and greatest stent without any control over usage. Even bare-metal stents may be overused.
The Motley Fool March 29, 2007 Michael P. Cecil	Stents on Trial New study results could affect stent sales -- at least in the short term.
BusinessWeek August 8, 2005 Amy Barrett	BW 50: In A Bind Over Stents Safety concerns about drug-coated stents from Johnson & Johnson and Boston Scientific could open the way for rivals.
BusinessWeek September 9, 2010 Michelle Cortez	Coming Soon: Dissolvable Stents New stents from Abbott Labs and others appear to reduce the risk of blood clots
The Motley Fool August 6, 2004 Jeff Hwang	Stent Recall Stings Medical device maker Boston Scientific's recall has happened at a crucial time. Will the company lose its market share?
The Motley Fool June 15, 2011 Brian Orelli	Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market.
Fast Company February 1, 2008 Amy Feldman	Artery, Heal Thyself Abbott's new absorbable stent could change heart surgery and revive a $5 billion business.
The Motley Fool May 27, 2010 Brian Orelli	Ever-Evolving Stent Technology (and How to Profit From It) Stay ahead of the curve.
The Motley Fool December 13, 2006 Stephen Albainy-Jenei	The Latest Standpoint on Stents A panel of experts reaches mixed conclusions on the safety and effectiveness of drug-coated stents. Investors, take note.
The Motley Fool October 8, 2007 Billy Fisher	Vital Signs at Medtronic The FDA raises question about Medtronic's Endeavor stent. Investors, remember that the company also has a well-diversified product portfolio to protect itself against any unforeseen pitfalls ahead.
BusinessWeek October 29, 2007 Arlene Weintraub	Heart Trouble The tiny stent sparked a lucrative industry - and made Dr. Samin Sharma a star. Then questions arose about the device's safety and efficacy.
BusinessWeek October 29, 2007 Arlene Weintraub	Medtronic's Uncertain Endeavor The drug-coated stent might have made up for Medtronic's recent product recall, but renewed scrutiny of the device has executives scaling back expectations
The Motley Fool April 8, 2005 Stephen D. Simpson	Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse?
The Motley Fool March 8, 2005 Stephen D. Simpson	The Stent Wars Continue Although Boston Scientific and Johnson & Johnson have been beating each other silly for market share, recent clinical data suggest little functional difference between drug-coated stents.
The Motley Fool September 25, 2008 Brian Orelli	Uh-Oh, Stent Makers Drugs are just as good as stents.
The Motley Fool August 29, 2008 Brian Orelli	Stent Makers Getting Desperate Johnson & Johnson, the first company to bring a drug-eluting stent to the U.S. market, seems like it might be getting a little desperate, as competition increases.
BusinessWeek June 20, 2005 Spencer E. Ante	Powering Through Clogged Arteries FoxHollow's SilverHawk is a promising alternative to stents and bypass surgery.
The Motley Fool February 2, 2004 Alyce Lomax	Boston Scientific's Stent Hopes Nice quarter, but all eyes should be on the Taxus stent.
The Motley Fool May 28, 2009 Brian Orelli	Boston Scientific Back in an Atomic Way Can its tiny stent save the day?
Chemistry World November 25, 2010 Hayley Birch	Designing safer stents for heart patients A study by UK researchers provides insights into how the body reacts to the metal stents used to wedge open blocked blood vessels in heart patients.
The Motley Fool November 17, 2006 Brian Lawler	Johnson & Johnson's Good Deal If Conor's stent design can alleviate some of the perceived safety worries about stents, then sales from the Cordis division should spring back up, again making it drive revenue growth for Johnson & Johnson, as it did before this year. Investors, take note.
The Motley Fool July 19, 2005 Stephen D. Simpson	Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note.
BusinessWeek September 22, 2003 Faith Arner	When Will This Stent See Circulation? Boston Scientific must clear the FDA, among other hurdles.
BusinessWeek July 18, 2005 John Carey	Is Heart Surgery Worth It? Physicians are questioning whether bypasses and angioplasties necessarily prolong patients' lives.
The Motley Fool January 12, 2007 Billy Fisher	Big Week at Boston Scientific The company's off to a great start so far for 2007. Investors, take note.
The Motley Fool July 26, 2004 W.D. Crotty	Boston Scientific on the Rebound The medical device maker posts robust earnings, softening the blow of the stent delivery system recall.
The Motley Fool October 23, 2008 Brian Orelli	Boston Scientific Should Be Thankful The medical device maker's two-year-old acquisition of Guidant has saved it in the third quarter.
The Motley Fool February 24, 2004 Alyce Lomax	J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain?
The Motley Fool December 17, 2007 Brian Orelli	A Range of Changes for Stent Makers The FDA is about to make it harder for drug-eluting stents to win its approval.
The Motley Fool October 13, 2008 Brian Orelli	Too Little Too Late for Boston Scientific The company gets new stent approved, but it should have happened earlier.
The Motley Fool July 6, 2007 Billy Fisher	Medtronic: For the Broken-Hearted Promising clinical trial could bring a new Medtronic stent to market. Investors, take note.
The Motley Fool March 27, 2008 Brian Orelli	Tougher Rules Could Help Stent Makers The FDA has finally issued draft guidance on the minimum requirements that it thinks companies need to fulfill to get drug-eluting stents approved.
The Motley Fool November 28, 2007 Brian Orelli	Abbott's Future as a Stent Maker The FDA likes Abbott's new drug-eluting stent; it seems likely the advisory committee will recommend that it be approved.
The Motley Fool February 1, 2005 Stephen D. Simpson	Stent Maker's Hearty Returns Medical device company Boston Scientific rebounds from cardiac stent recall with strong growth.
BusinessWeek October 9, 2006	Boston Scientific's Double Bypass First, quality problems with its defibrillators. Now, doubts about the safety of Boston Scientific's coated stents
The Motley Fool September 17, 2007 Brian Orelli	Can't See the Trees for the Forest Meta-analysis finds J&J's drug-coated stents are safer than Boston Scientific's stents, maybe. Can J&J use the complex study results to help their falling stent sales?
Managed Care February 2007 Maggie Mahar	Why Market Competition Will Not Mend Our Health Care System Doctors have a saying: 'Half of what we know is wrong.' In which half is the conventional wisdom that competition is society's best hope for improving quality and controlling costs?
The Motley Fool July 23, 2007 Ryan Fuhrmann	Boston Scientific Still Drowsy Facing continued top-line weakness, the medical device company may have to cut costs. Investors, take note.
The Motley Fool August 14, 2008 Brian Orelli	Wald Equation Won't Derail Boston Scientific The Wall Street Journal reanalyzes Boston Scientific's data on its new drug-eluding stent, but will the FDA care?
The Motley Fool May 20, 2009 Brian Orelli	Johnson & Johnson Tries to Pull a Travolta Johnson & Johnson seems to be making a comeback, after its drug-eluting stent market share fell precipitously to just 15% in the first quarter.
The Motley Fool April 19, 2005 Stephen D. Simpson	Stent Success Propels Boston Scientific The medical device company's still ahead of the competition. Companies dependent upon one product line may be riskier than average, but there's no question that they can reap big-time profits when business is good.
HBS Working Knowledge November 22, 2004 Martha Lagace	Does the Medical Industry Deliver Value? When the discussion turns to healthcare reform, we get sidetracked on issues such as soaring costs. The real issue is, what is the most effective way to treat a disease or condition?
The Motley Fool April 23, 2008 Brian Orelli	Boston Scientific Gets It Done After a rough 2007, it looks like Boston Scientific is turning itself around from the bottom up.